Liming Lin1, Cheng Jin2, Xiaoming Wei2, Huiying Li2, Jihong Shi2, Shouling Wu2, Xiaojie Yang3, Xiangqian Qi4. 1. Tianjin Teda International Cardiovascular Hospital, Cardiovascular Clinical Hospital, Tianjin Medical University61 Third Street, Tianjin Economic and Technological Development Area, Tianjin 300070, P. R. China; Tangshan Kailuan General Hospital57 East Xinhua Street, Tangshan 063000, Hebei Province, P. R. China. 2. Tangshan Kailuan General Hospital 57 East Xinhua Street, Tangshan 063000, Hebei Province, P. R. China. 3. Tangshan Maternal and Child Health Hospital Tangshan 063000, Hebei Province, P. R. China. 4. Tianjin Teda International Cardiovascular Hospital, Cardiovascular Clinical Hospital, Tianjin Medical University 61 Third Street, Tianjin Economic and Technological Development Area, Tianjin 300070, P. R. China.
Abstract
OBJECTIVE: The aim of this study is to examine and compare the efficacy of everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in coronary heart disease in diabetic or non-diabetic patients. METHODS: A total of 666 patients needed for percutaneous coronary intervention were randomly selected from June 2008 to June 2013 in our hospital and were divided into two groups: (i) coronary heart disease with diabetes group and (ii) non-diabetes group. Patients in each group were further assigned to receive treatment of either EES or ZES. Then we observed the major adverse cardiac events, including mortality, nonfatal myocardial infarction and non-fatal cerebrovascular events over the period of 15 months after initial stent implantation. RESULTS: Compared to the non-diabetic group, more patients in diabetic group had received anti-hypotensive treatment (72% vs. 49%, P < 0.0001) and hypolipemic treatment (80% vs. 67%, P < 0.0001) before the percutaneous coronary intervention. In both diabetic group and non-diabetic group, patients received ZES treatment had a much greater incidence rate of major adverse cardiac events compared to the patients received EES treatment (P < 0.05). Meanwhile, target lesion revascularization rate in the ZES group was also significantly higher than that in the EES group. The data showed big differences between ZES and EES groups with important statistical significance (P < 0.05). CONCLUSION:Patients with coronary heart disease and diabetes have a higher risk of major adverse cardiac events after stent implantation. EES treatment is safer with higher efficacy in our study, being a more effective stent for the patients merged with diabetes.
RCT Entities:
OBJECTIVE: The aim of this study is to examine and compare the efficacy of everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in coronary heart disease in diabetic or non-diabeticpatients. METHODS: A total of 666 patients needed for percutaneous coronary intervention were randomly selected from June 2008 to June 2013 in our hospital and were divided into two groups: (i) coronary heart disease with diabetes group and (ii) non-diabetes group. Patients in each group were further assigned to receive treatment of either EES or ZES. Then we observed the major adverse cardiac events, including mortality, nonfatal myocardial infarction and non-fatal cerebrovascular events over the period of 15 months after initial stent implantation. RESULTS: Compared to the non-diabetic group, more patients in diabetic group had received anti-hypotensive treatment (72% vs. 49%, P < 0.0001) and hypolipemic treatment (80% vs. 67%, P < 0.0001) before the percutaneous coronary intervention. In both diabetic group and non-diabetic group, patients received ZES treatment had a much greater incidence rate of major adverse cardiac events compared to the patients received EES treatment (P < 0.05). Meanwhile, target lesion revascularization rate in the ZES group was also significantly higher than that in the EES group. The data showed big differences between ZES and EES groups with important statistical significance (P < 0.05). CONCLUSION:Patients with coronary heart disease and diabetes have a higher risk of major adverse cardiac events after stent implantation. EES treatment is safer with higher efficacy in our study, being a more effective stent for the patients merged with diabetes.
Authors: Joseph Yeboah; Raimund Erbel; Joseph Chris Delaney; Robin Nance; Mengye Guo; Alain G Bertoni; Matthew Budoff; Susanne Moebus; Karl-Heinz Jöckel; Gregory L Burke; Nathan D Wong; Nils Lehmann; David M Herrington; Stefan Möhlenkamp; Philip Greenland Journal: Atherosclerosis Date: 2014-08-14 Impact factor: 5.162
Authors: Marco Valgimigli; Athanasios Patialiakas; Attila Thury; Salvatore Colangelo; Gianluca Campo; Matteo Tebaldi; Imre Ungi; Stefano Tondi; Marco Roffi; Alberto Menozzi; Nicoletta de Cesare; Roberto Garbo; Emanuele Meliga; Luca Testa; Henrique M Gabriel; Flavio Airoldi; Marco Ferlini; Francesco Liistro; Antonio Dellavalle; Pascal Vranckx; Carlo Briguori Journal: Am Heart J Date: 2013-09-26 Impact factor: 4.749
Authors: Raffaele Piccolo; Giulio G Stefanini; Anna Franzone; Ernest Spitzer; Stefan Blöchlinger; Dik Heg; Peter Jüni; Stephan Windecker Journal: Circ Cardiovasc Interv Date: 2015-04 Impact factor: 6.546
Authors: Doo Sun Sim; Myung Ho Jeong; Dae Sung Park; Jung Ha Kim; Kyung Seob Lim; Hyun Kuk Kim; Sung Soo Kim; Jae Yeong Cho; Hae Chang Jeong; Keun Ho Park; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park Journal: Korean Circ J Date: 2015-03-24 Impact factor: 3.243
Authors: Dean J Kereiakes; Ian T Meredith; Stephan Windecker; R Lee Jobe; Shamir R Mehta; Ian J Sarembock; Robert L Feldman; Bernardo Stein; Christophe Dubois; Timothy Grady; Shigeru Saito; Takeshi Kimura; Thomas Christen; Dominic J Allocco; Keith D Dawkins Journal: Circ Cardiovasc Interv Date: 2015-04 Impact factor: 6.546
Authors: Michael Maeng; Lisette O Jensen; Hans-Henrik Tilsted; Anne Kaltoft; Henning Kelbaek; Ulrik Abildgaard; Anton Villadsen; Jens Aarøe; Per Thayssen; Lars R Krusell; Evald H Christiansen; Hans E Bøtker; Steen D Kristensen; Jan Ravkilde; Morten Madsen; Henrik T Sørensen; Klaus Rasmussen; Leif Thuesen; Jens F Lassen Journal: Am J Cardiol Date: 2011-08-23 Impact factor: 2.778
Authors: Lakshmana K Pendyala; Joshua P Loh; Hironori Kitabata; Sa'ar Minha; Rebecca Torguson; Fang Chen; Lowell F Satler; William O Suddath; Augusto D Pichard; Ron Waksman Journal: J Interv Cardiol Date: 2014-08 Impact factor: 2.279
Authors: Michael Maeng; Lisette O Jensen; Anne Kaltoft; Hans H T Hansen; Morten Bøttcher; Jens F Lassen; Per Thayssen; Lars R Krusell; Klaus Rasmussen; Lars Pedersen; Henrik T Sørensen; Søren P Johnsen; Leif Thuesen Journal: Am J Cardiol Date: 2008-05-28 Impact factor: 2.778